Aurora Cannabis Inc. (ACB) Accused of Misleading Shareholders
According to the complaint for alleged violations of the Securities Exchange Act of 1934 between October 23, 2018 and January 6, 2020, throughout the relevant period, due to Aurora Cannabis, Inc. (ACB)’s exaggerated representation of its market demand, the Company was overproducing consumer use cannabis products, leading to production inefficiencies. As a result, on November 14, 2019, Aurora released dismal fiscal first quarter 2020 financial results that revealed a revenue decline of 24% quarter-over-quarter with net income of $10.4 million, compared to net income of $104.2 million for the same quarter last year. Then, on November 29, 2019, Marijuana Business Daily reported that Germany had stopped the sale of Aurora’s medical products while German authorities investigated Aurora’s proprietary process. Following these issues, on December 21, 2019, Aurora announced the abrupt departure of its Chief Corporate Officer also described as Aurora’s “public face.” Finally, as a consequence of its poor financial condition, on January 6, 2020, Aurora announced that it would be selling one of its greenhouses to raise cash, marking the third tangible asset Aurora had decided to offload. Following all of these disclosures, Aurora shares traded at around just $1.83, representing a decline of almost 45% from its closing price of $3.29 on November 14, 2019.
If you are a concerned shareholder who owns shares in ACB and would like more information about your rights and potential remedies you can call us toll-free at (855) TIM-MLAW (855-846-6529) or send us a message via the Shareholder Information below